{"id":1604,"date":"2026-01-21T16:17:25","date_gmt":"2026-01-21T15:17:25","guid":{"rendered":"https:\/\/imn.u-bordeaux.fr\/?p=1604"},"modified":"2026-01-21T16:17:25","modified_gmt":"2026-01-21T15:17:25","slug":"la-satt-aquitaine-investit-317-890-e-dans-le-projet-novel","status":"publish","type":"post","link":"https:\/\/imn.u-bordeaux.fr\/fr\/2026\/01\/21\/la-satt-aquitaine-investit-317-890-e-dans-le-projet-novel\/","title":{"rendered":"La SATT Aquitaine investit 317 890 \u20ac dans le projet NOVEL"},"content":{"rendered":"<p><span id=\"hs_cos_wrapper_post_body\" class=\"hs_cos_wrapper hs_cos_wrapper_meta_field hs_cos_wrapper_type_rich_text\" data-hs-cos-general-type=\"meta_field\" data-hs-cos-type=\"rich_text\">La SATT Aquitaine d\u00e9cide d\u2019investir \u00e0 hauteur de 317 890\u20ac (dont 40 000\u20ac dans la propri\u00e9t\u00e9 intellectuelle) dans le d\u00e9veloppement du projet NOVEL, une innovation de rupture visant \u00e0 d\u00e9velopper un traitement modificateur pour la maladie de Parkinson et l\u2019atrophie multisyst\u00e9matis\u00e9e. Aucun traitement actuel ne permet d\u2019en ralentir la progression de ces deux pathologies neurod\u00e9g\u00e9n\u00e9ratives, parmi les plus invalidantes.\u00a0<\/span><\/p>\n<h3>Le projet<\/h3>\n<p><span id=\"hs_cos_wrapper_post_body\" class=\"hs_cos_wrapper hs_cos_wrapper_meta_field hs_cos_wrapper_type_rich_text\" data-hs-cos-general-type=\"meta_field\" data-hs-cos-type=\"rich_text\">L\u2019ambition du projet NOVEL est de restaurer la capacit\u00e9 des cellules \u00e0 d\u00e9grader les prot\u00e9ines mal conform\u00e9es et leurs agr\u00e9gats. La strat\u00e9gie repose sur un nanovecteur, con\u00e7u pour cibler les lysosomes (des organites cl\u00e9s dans la d\u00e9gradation cellulaire) et augmenter leur activit\u00e9 de d\u00e9gradation de l\u2019\u03b1-synucl\u00e9ine. Cette approche vise \u00e0 ralentir, voire \u00e0 stabiliser, la progression de la maladie. Elle offrirait une meilleure qualit\u00e9 de vie et une autonomie prolong\u00e9e pour le patient, ainsi qu\u2019une augmentation plus tardive des doses des traitements dopaminergiques, r\u00e9duisant ainsi leurs effets secondaires.\u00a0<\/span><\/p>\n<h3>Les porteurs de projets<\/h3>\n<p><span id=\"hs_cos_wrapper_post_body\" class=\"hs_cos_wrapper hs_cos_wrapper_meta_field hs_cos_wrapper_type_rich_text\" data-hs-cos-general-type=\"meta_field\" data-hs-cos-type=\"rich_text\">NOVEL est port\u00e9 par une \u00e9quipe de recherche pluridisciplinaire associant des expertises compl\u00e9mentaires en neurosciences et chimie. A l\u2019origine du projet\u00a0: Benjamin Dehay, Directeur de Recherche Inserm \u00e0 l\u2019Institut des Maladies Neurod\u00e9g\u00e9n\u00e9ratives (<a href=\"https:\/\/www.imn-bordeaux.org\/\" target=\"_blank\" rel=\"noopener\">IMN<\/a> \u2013 universit\u00e9 de Bordeaux, CNRS), S\u00e9bastien Lecommandoux, Professeur \u00e0 Bordeaux INP et Directeur du Laboratoire de Chimie des Polym\u00e8res Organiques (<a href=\"https:\/\/www.lcpo.fr\/\" target=\"_blank\" rel=\"noopener\">LCPO<\/a> \u2013 universit\u00e9 de Bordeaux, CNRS, Bordeaux INP) et Philippe Barth\u00e9l\u00e9my, Directeur du laboratoire Acides nucl\u00e9iques : R\u00e9gulations Naturelles et Artificielles (<a href=\"https:\/\/arna.cnrs.fr\/\" target=\"_blank\" rel=\"noopener\">ARNA<\/a> \u2013 Inserm, CNRS, universit\u00e9 de Bordeaux).<\/span><\/p>\n<p><a href=\"https:\/\/blog.ast-innovations.com\/maladies-neurod%C3%A9g%C3%A9n%C3%A9ratives-satt-aquitaine-investissement-strat%C3%A9gie-th%C3%A9rapeutique-innovante\">Pour plus d&rsquo;informations<\/a><span id=\"hs_cos_wrapper_post_body\" class=\"hs_cos_wrapper hs_cos_wrapper_meta_field hs_cos_wrapper_type_rich_text\" data-hs-cos-general-type=\"meta_field\" data-hs-cos-type=\"rich_text\"><\/span><\/p>\n<p><span id=\"hs_cos_wrapper_post_body\" class=\"hs_cos_wrapper hs_cos_wrapper_meta_field hs_cos_wrapper_type_rich_text\" data-hs-cos-general-type=\"meta_field\" data-hs-cos-type=\"rich_text\">Contact :\u00a0<a href=\"mailto:c.zabawinski@ast-innovations.com\" rel=\"noopener\">Christophe Zabawinski<\/a><\/span><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Projet port\u00e9 par Benjamin Dehay (IMN), S\u00e9bastien Lecommandoux (LCPO) et Philippe Barth\u00e9l\u00e9my (ARNA)<\/p>\n","protected":false},"author":8,"featured_media":1605,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-1604","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-quoi-de-neuf"],"_links":{"self":[{"href":"https:\/\/imn.u-bordeaux.fr\/fr\/wp-json\/wp\/v2\/posts\/1604","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/imn.u-bordeaux.fr\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/imn.u-bordeaux.fr\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/imn.u-bordeaux.fr\/fr\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/imn.u-bordeaux.fr\/fr\/wp-json\/wp\/v2\/comments?post=1604"}],"version-history":[{"count":1,"href":"https:\/\/imn.u-bordeaux.fr\/fr\/wp-json\/wp\/v2\/posts\/1604\/revisions"}],"predecessor-version":[{"id":1607,"href":"https:\/\/imn.u-bordeaux.fr\/fr\/wp-json\/wp\/v2\/posts\/1604\/revisions\/1607"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/imn.u-bordeaux.fr\/fr\/wp-json\/wp\/v2\/media\/1605"}],"wp:attachment":[{"href":"https:\/\/imn.u-bordeaux.fr\/fr\/wp-json\/wp\/v2\/media?parent=1604"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/imn.u-bordeaux.fr\/fr\/wp-json\/wp\/v2\/categories?post=1604"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/imn.u-bordeaux.fr\/fr\/wp-json\/wp\/v2\/tags?post=1604"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}